Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 11, 2009Annals of NeurologyOpen Access

Phase II trial of CoQ10 for ALS finds insufficient evidence to justify phase III

View Full Paper
Ask AI
Bookmark
Share

Authors

PKPetra KaufmannUniversity of the SciencesJTJohn L.P. ThompsonHeart Failure & TransplantGLGilberto LevyUniversidade do Estado do Rio de Janeiro

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Kaufmann et al. (2009) studied this question.

synapsesocial.com/papers/69dbdfb9e6ab964fb083713chttps://doi.org/10.1002/ana.21743
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1A responsive outcome for Parkinson's disease neuroprotection futility studies2005 · 71 citations
  2. 2Changes in the normal maximal expiratory flow-volume curve with growth and aging.1983 · 1,911 citations
  3. 3Cu/Zn superoxide dismutase (SOD1) mutations associated with familial amyotrophic lateral sclerosis (ALS) affect cellular free radical release in the presence of oxidative stress2002 · 57 citations
  4. 4Coenzyme Q<sub>10</sub> levels correlate with the activities of complexes I and II/III in mitochondria from parkinsonian and nonparkinsonian subjects1997 · 326 citations
  5. 5Selecting and Ordering Populations: A New Statistical Methodology2000 · 346 citations